Boueroy P, Chopjitt P, Hatrongjit R, Morita M, Sugawara Y, Akeda Y
PeerJ. 2023; 11:e16401.
PMID: 37953793
PMC: 10638923.
DOI: 10.7717/peerj.16401.
Abbara S, Guillemot D, Brun-Buisson C, Watier L
Antibiotics (Basel). 2022; 11(2).
PMID: 35203803
PMC: 8868523.
DOI: 10.3390/antibiotics11020201.
Samarinas M, Skriapas K, Mitsogiannis I, Gravas S, Karatzas A, Tzortzis V
Cent European J Urol. 2021; 73(4):544-550.
PMID: 33552582
PMC: 7848831.
DOI: 10.5173/ceju.2020.0072.
Van Nieuwkoop C, van der Starre W, Stalenhoef J, van Aartrijk A, van der Reijden T, Vollaard A
BMC Med. 2017; 15(1):70.
PMID: 28366170
PMC: 5376681.
DOI: 10.1186/s12916-017-0835-3.
Natale A, Stelling J, Meledandri M, Messenger L, DAncona F
Euro Surveill. 2017; 22(11).
PMID: 28333615
PMC: 5356424.
DOI: 10.2807/1560-7917.ES.2017.22.11.30484.
Clinical importance and epidemiology of quinolone resistance.
Kim E, Hooper D
Infect Chemother. 2015; 46(4):226-38.
PMID: 25566402
PMC: 4285002.
DOI: 10.3947/ic.2014.46.4.226.
Pyelonephritis Caused Solely by Escherichia hermanii.
Tong Y, Xin B, Sun S
Jundishapur J Microbiol. 2014; 7(5):e18138.
PMID: 25147714
PMC: 4138642.
DOI: 10.5812/jjm.18138.
Community acquired quinolone-resistant Escherichia coli pyelonephritis complicated with multiple renal abscesses: a case report.
Katsiari M, Nikolaou C, Roussou Z, Triantopoulou C, Apessou D, Platsouka E
Hippokratia. 2013; 16(4):381-3.
PMID: 23935324
PMC: 3738619.
Trends of mortality due to septicemia in Greece: an 8-year analysis.
Falagas M, Korbila I, Kapaskelis A, Manousou K, Leontiou L, Tansarli G
PLoS One. 2013; 8(7):e67621.
PMID: 23844042
PMC: 3699659.
DOI: 10.1371/journal.pone.0067621.
Ciprofloxacin-resistant Escherichia coli in Central Greece: mechanisms of resistance and molecular identification.
Mavroidi A, Miriagou V, Liakopoulos A, Tzelepi E, Stefos A, Dalekos G
BMC Infect Dis. 2012; 12:371.
PMID: 23259844
PMC: 3548683.
DOI: 10.1186/1471-2334-12-371.
Treatment duration of febrile urinary tract infections.
van der Starre W, van Dissel J, Van Nieuwkoop C
Curr Infect Dis Rep. 2011; 13(6):571-8.
PMID: 21882085
PMC: 3207126.
DOI: 10.1007/s11908-011-0211-y.
Emergence of and risk factors for ciprofloxacin-gentamicin-resistant Escherichia coli urinary tract infections in a region of Quebec.
Pepin J, Plamondon M, Lacroix C, Alarie I
Can J Infect Dis Med Microbiol. 2010; 20(4):e163-8.
PMID: 21119795
PMC: 2807251.
DOI: 10.1155/2009/971624.
Emergence of the plasmid-mediated quinolone resistance gene qnrS1 in Escherichia coli isolates in Greece.
Vasilaki O, Ntokou E, Ikonomidis A, Sofianou D, Frantzidou F, Alexiou-Daniel S
Antimicrob Agents Chemother. 2008; 52(8):2996-7.
PMID: 18490503
PMC: 2493102.
DOI: 10.1128/AAC.00325-08.
Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy.
Brown P, Ki M, Foxman B
Pharmacoeconomics. 2005; 23(11):1123-42.
PMID: 16277548
DOI: 10.2165/00019053-200523110-00005.
Fluoroquinolone-resistant Escherichia coli, Indonesia.
Kuntaman K, Lestari E, Severin J, Kershof I, Mertaniasih N, Purwanta M
Emerg Infect Dis. 2005; 11(9):1363-9.
PMID: 16229763
PMC: 3310614.
DOI: 10.3201/eid1109.041207.
Antimicrobial Selection in the Treatment of Pyelonephritis.
Brown P
Curr Infect Dis Rep. 2004; 6(6):457-461.
PMID: 15538983
DOI: 10.1007/s11908-004-0065-7.